FDA Adds Bemotrizinol to Approved Sunscreen Ingredients

The Food and Drug Administration has updated its Over-the-Counter Monograph M020, designating bemotrizinol as a generally recognized as safe and effective (GRASE) active ingredient for sunscreen products. This amendment allows for its use in concentrations up to 6 percent. The regulatory change, effective June 10, 2026, modifies the conditions for OTC sunscreen formulations.

Context

Bemotrizinol is a chemical compound that absorbs UV rays, providing protection against sun damage. The FDA's designation of this ingredient as GRASE follows a comprehensive review of its safety and efficacy. The update to the Over-the-Counter Monograph M020 is part of the FDA's broader initiative to regulate sunscreen ingredients more effectively.

Why it matters

The FDA's approval of bemotrizinol as a safe and effective sunscreen ingredient is significant as it expands the options available for sun protection. This change may enhance the effectiveness of sunscreen products, potentially improving public health outcomes related to skin cancer and sunburn. Additionally, it reflects ongoing efforts to ensure that sunscreen formulations meet safety standards.

Implications

The inclusion of bemotrizinol may lead to more effective sunscreen options for consumers, potentially reducing the incidence of sun-related health issues. Manufacturers may benefit from the ability to market new products that meet evolving safety standards. Consumers, particularly those with sensitive skin or specific sun protection needs, may find more suitable products available.

What to watch

The amendment will take effect on June 10, 2026, giving manufacturers time to reformulate their products. Stakeholders in the sunscreen industry will likely begin to explore new formulations incorporating bemotrizinol. Monitoring consumer response to these new products will be important as they enter the market.